RT Journal Article
SR Electronic
T1 Demographic and clinical profile of black patients with chronic kidney disease attending Charlotte Maxeke Johannesburg Academic Hospital (CMJAH) in Johannesburg, South Africa
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.16.22272477
DO 10.1101/2022.03.16.22272477
A1 Meremo, Alfred J.
A1 Paget, Graham
A1 Duarte, Raquel
A1 Dickens, Caroline
A1 Dix-Peek, Therese
A1 Bintabara, Deogratius
A1 Naicker, Saraladevi
YR 2022
UL http://medrxiv.org/content/early/2022/03/16/2022.03.16.22272477.abstract
AB Background The prevalence of chronic kidney disease (CKD) is increasing worldwide; black patients have an increased risk of developing CKD and end stage kidney disease (ESKD) at significantly higher rates than other races.Methods A cross sectional study was carried out on black patients with CKD attending the kidney outpatient clinic at Charlotte Maxeke Johannesburg Academic Hospital (CMJAH) in South Africa, between September 2019 to March 2020. Demographic and clinical data were extracted from the ongoing kidney outpatient clinic records and interviews, and were filled in a questionnaire. Patients provided blood and urine for laboratory investigations as standard of care, data were descriptively and inferentially analysed using STATA version 17. Multivariable logistic regression analysis was used to identify demographic and clinical data associated with advanced CKD.Results A total of 312 black patients with CKD were enrolled during the study period; 58% patients had advanced CKD, of whom 31.5 % had grossly increased proteinuria, 96.7 % had hypertension, 38.7 % had diabetes mellitus and 38.1 % had both hypertension and diabetes mellitus. For patients with advanced CKD, the median age was 61 (IQR 51-69) years, eGFR 33 (30 -39) mL/min/1.73 m2, serum bicarbonate 22 (IQR 20 – 24), hemoglobin 12.9 (IQR 11.5 – 14.0) g/dl, serum transferrin 2.44 (IQR 2.23 – 2.73) g/L, serum uric acid 0.43 (IQR 0.37 – 0.53) and serum potassium 4.4 (IQR 3.9 – 4.8) mmol/L. The prevalence of metabolic acidosis was 62.4 %, anemia 46.4 %, gout 30.9 %, low transferrin levels 16.6 % and hyperkalemia 8.8 % among those with advanced CKD, while the prevalence of metabolic acidosis and anemia was 46.6 % and 25.9 % respectively in those with early CKD. Variables with higher odds for advanced CKD after multivariable logistic regression analysis were hypertension (OR 3.3, 95 % CI 1.2 - 9.2, P = 0.020), diabetes mellitus (OR 1.8, 95 % CI 1.1 - 3.3, P = 0.024), severe proteinuria (OR 3.5, 95 % CI 1.9 - 6.5, P = 0.001), angina (OR 2.5, 95 % CI 1.2 - 5.1, P = 0.008), anaemia (OR 2.9, 95% CI 1.7 - 4.9, P= 0.001), hyperuricemia (OR 2.4, 95 % CI 1.4 - 4.1, P = 0.001), and metabolic acidosis (OR 2.0, 95% CI 1.2 - 3.1, P= 0.005). Other associations with advanced CKD were widow/widower (OR 3.2, 95 % CI 1.4 - 7.4, P = 0.006), low transferrin (OR 2.4, 95% CI 1.1 - 5.1, P= 0.028), hyperkalemia (OR 5.4, 95% CI 1.2 - 24.1, P= 0.029), allopurinol (OR 2.4, 95 % CI 1.4 - 4.3, P = 0.005) and doxazosin (OR 1.9, 95% CI 1.2 - 3.1, P = 0.006).Conclusion Hypertension and diabetes mellitus were strongly associated with advanced CKD, suggesting a need for primary and secondary population-based prevention measures. Metabolic acidosis, anaemia with low transferrin levels, hyperuricemia and hyperkalemia were highly prevalent in our patients, including those with early CKD, and they were strongly associated with advanced CKD, calling for the proactive role of clinicians and dietitians in supporting the needs of CKD patients in meeting their daily dietary requirements towards preventing and slowing the progression of CKD.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors received no specific funding for this workAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was obtained from the Human Research Ethics Committee of the University of Witwatersrand, Johannesburg (ethics clearance certificate No. M190553). Informed consent was obtained from each of the participants before embarking on data collection.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Not ApplicableAll relevant data are within the manuscript and its Supporting Information files.CKDchronic kidney diseasesCMJAHCharlotte Maxeke Johannesburg Academic HospitalCKD-EPIchronic kidney disease epidemiology collaborationESKDend stage kidney diseaseT2DMType 2 Diabetes MellituseGFRestimated glomerular filtration rateIDMSisotope dilution mass spectroscopyuPCRurine protein creatinine ratioCCBscalcium channel blockersACEIsangiotensin converting enzyme inhibitorsARBsAldosterone receptors blockersKDIGOkidney disease improving global outcomesNCDsnon-communicable diseasesSSAsub Saharan Africa